JP2005320323A - Lipase inhibitor - Google Patents
Lipase inhibitor Download PDFInfo
- Publication number
- JP2005320323A JP2005320323A JP2005111714A JP2005111714A JP2005320323A JP 2005320323 A JP2005320323 A JP 2005320323A JP 2005111714 A JP2005111714 A JP 2005111714A JP 2005111714 A JP2005111714 A JP 2005111714A JP 2005320323 A JP2005320323 A JP 2005320323A
- Authority
- JP
- Japan
- Prior art keywords
- lipase
- lipase inhibitor
- dried
- extract
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940086609 Lipase inhibitor Drugs 0.000 title claims abstract description 11
- 208000008589 Obesity Diseases 0.000 claims abstract description 13
- 235000020824 obesity Nutrition 0.000 claims abstract description 13
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 9
- 241000208340 Araliaceae Species 0.000 claims description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 10
- 235000008434 ginseng Nutrition 0.000 claims description 10
- 241000544061 Cuculus canorus Species 0.000 claims description 7
- 235000004347 Perilla Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 244000194101 Ginkgo biloba Species 0.000 claims description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 4
- 235000011201 Ginkgo Nutrition 0.000 claims description 3
- 241000237509 Patinopecten sp. Species 0.000 claims description 3
- 241000251184 Rajiformes Species 0.000 claims description 3
- 235000020637 scallop Nutrition 0.000 claims description 3
- 241000218691 Cupressaceae Species 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 102000004882 Lipase Human genes 0.000 abstract description 9
- 108090001060 Lipase Proteins 0.000 abstract description 9
- 239000004367 Lipase Substances 0.000 abstract description 9
- 235000019421 lipase Nutrition 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 241000382951 Hansenia forbesii Species 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 235000003826 Artemisia Nutrition 0.000 abstract description 3
- 241001435059 Artemisia argyi Species 0.000 abstract description 3
- 235000010894 Artemisia argyi Nutrition 0.000 abstract description 3
- 241000092666 Artemisia iwayomogi Species 0.000 abstract description 3
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract description 3
- 235000004348 Perilla frutescens Nutrition 0.000 abstract description 3
- 244000030166 artemisia Species 0.000 abstract description 3
- 235000009052 artemisia Nutrition 0.000 abstract description 3
- 240000004510 Agastache rugosa Species 0.000 abstract description 2
- 235000010686 Agastache rugosa Nutrition 0.000 abstract description 2
- 241001168876 Artemisia lavandulifolia Species 0.000 abstract description 2
- 244000231729 Astrocaryum tucuma Species 0.000 abstract description 2
- 240000009146 Blepharocalyx salicifolius Species 0.000 abstract description 2
- 244000306301 Caesalpinia sappan Species 0.000 abstract description 2
- 235000015162 Caesalpinia sappan Nutrition 0.000 abstract description 2
- 240000002779 Cayratia japonica Species 0.000 abstract description 2
- 240000000425 Chaenomeles speciosa Species 0.000 abstract description 2
- 235000005078 Chaenomeles speciosa Nutrition 0.000 abstract description 2
- 244000227573 Desmodium styracifolium Species 0.000 abstract description 2
- 241000893536 Epimedium Species 0.000 abstract description 2
- 241001016310 Epimedium grandiflorum Species 0.000 abstract description 2
- 241001362411 Epimedium sagittatum Species 0.000 abstract description 2
- 241001149422 Ganoderma applanatum Species 0.000 abstract description 2
- 241000533388 Hansenia weberbaueriana Species 0.000 abstract description 2
- 241000007358 Magnolia biondii Species 0.000 abstract description 2
- 241000218394 Magnolia liliiflora Species 0.000 abstract description 2
- 241000123113 Phellinus igniarius Species 0.000 abstract description 2
- 241001080798 Polygala tenuifolia Species 0.000 abstract description 2
- 244000226566 Psoralea corylifolia Species 0.000 abstract description 2
- 241000123889 Rubus chingii Species 0.000 abstract description 2
- 241001618264 Rubus coreanus Species 0.000 abstract description 2
- 244000111494 Rubus morifolius Species 0.000 abstract description 2
- 241001302463 Viola mandshurica Species 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 240000002505 Pogostemon cablin Species 0.000 abstract 1
- 235000011751 Pogostemon cablin Nutrition 0.000 abstract 1
- 240000005255 Rubus parvifolius Species 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 21
- 229940126678 chinese medicines Drugs 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 229940040461 lipase Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 102000019280 Pancreatic lipases Human genes 0.000 description 4
- 108050006759 Pancreatic lipases Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 229940116369 pancreatic lipase Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 description 2
- 241001063197 Ostericum grosseserratum Species 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 241001638289 Polygala japonica Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- -1 etc. are blended Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 235000021012 strawberries Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- NKQFKJYKCVDLPT-KHPPLWFESA-N (4-methyl-2-oxochromen-7-yl) (z)-octadec-9-enoate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C21 NKQFKJYKCVDLPT-KHPPLWFESA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241001254604 Angelica pubescens Species 0.000 description 1
- 244000024251 Aralia cordata Species 0.000 description 1
- 235000014722 Aralia cordata Nutrition 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000437896 Corydalis bungeana Species 0.000 description 1
- 241000272177 Cuculiformes Species 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000123871 Gueldenstaedtia verna Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 240000001076 Osbeckia chinensis Species 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 235000006990 Pimenta dioica Nutrition 0.000 description 1
- 240000008474 Pimenta dioica Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000251905 Pseudocydonia sinensis Species 0.000 description 1
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000012232 skeletal muscle contraction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000000152 swallowing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000009160 urethral calculus Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、長期間服用しても安全で有効なリパーゼ阻害剤に関する。 The present invention relates to a lipase inhibitor that is safe and effective even when taken for a long period of time.
近年、食習慣、運動習慣、休養、喫煙、飲酒などの生活習慣がその発症・進行に影響を及ぼすとされている生活習慣病が注目されている。先進諸国においては、食習慣、運動習慣との関連が大きいとされる肥満、高脂血症、インスリン非依存型糖尿病(II型糖尿病)、高血圧などの増加が国民の健康維持に支障をきたし、生活の質の低下を招くばかりでなく、国民医療費の急激な増加を引き起こすなど、大きな社会問題となってきている。 In recent years, lifestyle-related diseases, for which lifestyle habits such as eating habits, exercise habits, rest, smoking, and alcohol consumption are thought to affect the onset and progression of the disease, have attracted attention. In developed countries, increases in obesity, hyperlipidemia, non-insulin dependent diabetes mellitus (type II diabetes), high blood pressure, etc., which are said to be related to eating habits and exercise habits, have hindered people's health maintenance. Not only does it lead to a decline in the quality of life, it has also become a major social problem, causing a rapid increase in national medical expenses.
膵臓から分泌されるリパーゼ(膵リパーゼ)は消化管における脂質の消化酵素である。食事により摂取された脂質のうち、トリグリセライドは膵リパーゼによって脂肪酸とモノグリセライドに分解されて小腸から吸収される。膵リパーゼの活性を阻害する組成物は、消化管からの脂質吸収を阻害するのみではなく、体内の脂質蓄積を抑制して高脂血症及び/又は肥満の予防又は改善に有効であると考えられる(非特許文献1)。 Lipase secreted from the pancreas (pancreatic lipase) is a lipid digestive enzyme in the digestive tract. Of the lipids ingested by diet, triglycerides are broken down into fatty acids and monoglycerides by pancreatic lipase and absorbed from the small intestine. A composition that inhibits the activity of pancreatic lipase not only inhibits lipid absorption from the gastrointestinal tract, but also suppresses lipid accumulation in the body and is considered to be effective in preventing or improving hyperlipidemia and / or obesity. (Non-Patent Document 1).
天然物由来のリパーゼ阻害剤としては、阿仙薬、グアバの葉、メドウスゥイートの葉の溶媒抽出物を配合したリパ−ゼ阻害剤(特許文献1)、レモングラス、オールスパイス、シナモン、クローブの植物又はその抽出物を有効成分とするリパーゼ阻害剤(特許文献2)、アルファルファ抽出物、苦丁茶抽出物、金銀花抽出物、ペパーミント抽出物、チョウジ抽出物、セイヨウキズタ抽出物、オリーブ抽出物及びラフマ茶抽出物を有効成分とするリパーゼ阻害剤(特許文献3)などが開示されている。 Examples of lipase inhibitors derived from natural products include lipase inhibitors (Patent Document 1) containing a solvent extract of Asen, Guava leaves, and Meadow Sweet leaves, Lemongrass, Allspice, Cinnamon, and Clove plants. Or a lipase inhibitor containing the extract as an active ingredient (Patent Document 2), alfalfa extract, bitter tea extract, gold-silver flower extract, peppermint extract, clove extract, squirrel extract, olive extract and A lipase inhibitor containing Raffma tea extract as an active ingredient (Patent Document 3) is disclosed.
モッカ(木瓜)は、バラ科のボケ(Chaenomeles speciosa)の成熟果実を横割りもしくは縦割りして乾燥したもの、又はカリン(Pseudocydonia sinensis)の成熟果実を2縦割して乾燥したものなどがあり、鎮咳、鎮痛及び利水薬としての用途が知られている(非特許文献2)。 Mokka (mosquito) is dried by splitting or vertically dividing the mature fruit of Rosaceae (Chaenomeles speciosa), or dried by vertically splitting the mature fruit of Karin (Pseudocydonia sinensis) The use as an antitussive, an analgesic, and a water-use drug is known (nonpatent literature 2).
フクボンシ(覆盆子)は、バラ科のゴショイチゴ(Rubus chingii)の未成熟果実、クマイチゴ(R. crataegifolius)の果実、トックリイチゴ(R. coreanus)の果実及びカラナワシロキイチゴ(R. parvifolius)の果実を乾燥したものであり、霍乱弧菌の生長抑制作用があり、強壮及び強精薬としての用途が知られている(非特許文献3)。また、ゴショイチゴ、トックリイチゴから抽出されたGODタイプのエラジタンニンに糖質分解酵素阻害作用が知られており(特許文献4)、血糖値の上昇抑制や肥満防止の用途が開示されている。 Fukubonshi is an immature fruit of Rubus chingii, a fruit of R. crataegifolius, a fruit of R. coreanus and a fruit of Rana parvifolius Is dried, has a growth-inhibiting action of disturbed arc bacteria, and is known for its use as a tonic and a strong drug (Non-patent Document 3). In addition, GOD-type ellagitannins extracted from gosho strawberries and toccoli strawberries are known to have an inhibitory action on saccharide-degrading enzymes (Patent Document 4), and their uses for suppressing an increase in blood glucose level and preventing obesity are disclosed.
インヨウカク(淫羊カク)は、メギ科のホザキノイカリソウ(Epimedium sagittatum)、ヤチマタイカリソウ(E. grandiflorum)などEpimedium属植物の全草又は葉を乾燥したものであり、強精及び強壮薬としての用途が知られている(非特許文献4)。 Inyo-kaku (deer sheep oyster) is a dried plant of whole plants or leaves of Epimedium genus plants such as the barberry family Epimedium sagittatum and E. grandiflorum. The use is known (nonpatent literature 4).
オンジ(遠志)は、ヒメハギ科のイトヒメハギ(Polygala tenuifolia)の根もしくは根皮を乾燥したものであり、唾液及び気管支粘膜分泌物の増加作用や子宮収縮及び筋緊張作用があり、鎮静、去痰及び抗炎症薬としての用途が知られている(非特許文献5)。 Onji is the dried root or root bark of Polygala tenuifolia, which has the effect of increasing salivary and bronchial mucosal secretions, uterine contraction and muscle tone, and sedation, expectoration and The use as an inflammatory drug is known (Non-patent Document 5).
カントンキンセンソウ(広東金銭草)は、マメ科のDesmodium styracifoliumの全草を乾燥したものであり、利胆作用が知られており、胆嚢結石、黄疸性肝炎及び尿道結石などの治療に応用されている(非特許文献6)。 Canton ginseng (Guangdong goldgrass) is a dried product of leguminous Desmodium styracifolium, known for its biliary action and applied to the treatment of gallbladder stones, jaundice hepatitis and urethral stones. (Non-patent document 6).
ジチョウ(地丁)は、スミレ科のスミレ(Viola mandshurica)又はコスミレ(V. japonica)などスミレ属植物の全草を乾燥したもの(紫花地丁)、マメ科のイヌゲンゲ(Amblytropis multiflora)の根あるいは根をつけた全草を乾燥したもの(甜地丁)、ケシ科のCorydalis bungeanaの全草を乾燥したもの(苦地丁)、リンドウ科のGentiana loureiriiの全草を乾燥したもの(華南地丁)、ヒメハギ科のヒメハギ(Polygala japonica)の全草を乾燥したもの(竹葉地丁)、又はノボタン科のヒメノボタン(Osbeckia chinensis)の全草を乾燥したもの(紫地丁)であり、抗菌作用が知られており、解毒、抗炎症及び鎮痛薬として用いられている(非特許文献7)。 Ginkgo biloba is a dried violet vegetation such as violet (Viola mandshurica) or cosme (V. japonica) (purple flower edible), leguminous lobster (Amblytropis multiflora) root or Dried whole grass with roots (Kojichi), Dried poppy (Corydalis bungeana) (Dream), Gentiana loureirii (Drynaceae) ), Dried whole plant of Polygala japonica (Polygala japonica), dried dried whole plant (Osbeckia chinensis) (Purple), antibacterial It is known for its action and is used as a detoxifier, anti-inflammatory and analgesic (Non-Patent Document 7).
ソウオウ(桑黄)は、サルノコシカケ科のコフキサルノコシカケ(Elfvingia applanata)、又はキコブタケ科のキコブタケ(Phellinus igniarius)の子実体を乾燥したものであり、駆オ血及び止血薬としての用途が知られている(非特許文献8)。 Souou (Mulberry Yellow) is a dried fruit body of Elfvingia applanata or Phellinus igniarius, and is known for its use as an antitumor and hemostatic agent. (Non-patent document 8).
シンイ(辛夷)は、モクレン科のMagnolia biondii、シモクレン(M. liliflora)又はタムシバ(M. salicifolia)などの花蕾を乾燥したものであり、骨格筋収縮作用、降圧作用又は抗菌作用等があり、鎮静及び鎮痛薬としての用途が知られている(非特許文献9)。 Shini is a dried floret such as Magnolia biondii, M. liliflora or M. salicifolia of the magnolia family, and has skeletal muscle contraction action, antihypertensive action or antibacterial action, etc. And the use as an analgesic is known (nonpatent literature 9).
インチンコウ(茵チン蒿)は、キク科のカワラヨモギ(Artemisia capillaris)の幼苗、花穂又は帯花枝葉を乾燥したもの、同Artemisia属の幼苗を乾燥したもの、又はイワヨモギ(A. iwayomogi)の茎葉を乾燥したものであり、利胆作用、腸管や子宮の運動抑制作用、又は殺菌作用が知られており、消炎性利尿及び利胆薬として用いられる(非特許文献10)。 Inchinkou (A. iwayomogi) is a dried seedling of Artemisia capillaris, dried ears or stalks, dried young seedlings of the genus Artemisia, or dried stems of A. iwayomogi It is known to have a bile effect, an intestinal or uterine movement-inhibiting action, or a bactericidal action, and is used as an anti-inflammatory diuretic and a bile medicine (Non-patent Document 10).
キョウカツ(羌活)は、セリ科のNotopterygium incisum、N. forbesii又はN. forbesii var. oviformeの根茎を乾燥したもの、チョウセンオニウド(Ostericum koreanum)又はニオイウド(O. grosseserratum)の根と根茎を乾燥したもの、シシウド(Angelica pubescens)の根又は根茎を乾燥したもの、又はウコギ科のウド(Aralia cordata)の根を乾燥したものであり、鎮痛、鎮痙及び新陳代謝賦活薬としての用途が知られている(非特許文献11)。 Kyoukatsu (dried) dried roots and rhizomes of Notopterygium incisum, N. forbesii or N. forbesii var. Oviforme, Ostericum koreanum or O. grosseserratum , Dried roots and rhizomes of Angelica pubescens, or dried roots of Aralia cordata, known for use as analgesic, antispasmodic and metabolic stimulants ( Non-patent document 11).
カッコウ(カッ香)は、シソ科のパチョリ(Pogostemon cablin)の全草又は葉を乾燥したもの、又はカワミドリ(Agastache rugosa)の全草を乾燥したものであり、抗菌作用が知られており、芳香性健胃薬及び発表薬として用いられる(非特許文献12)。 Cuckoo (Cuckoos) is a dried plant or leaf of Pagostemon cablin, or a dried plant of Agastache rugosa, and has a known antibacterial effect. It is used as a sex stomachic medicine and a published medicine (Non-patent Document 12).
ガイヨウ(艾葉)は、キク科のArtemisia argyi、ヨモギ(A. princeps)、A. lavandulaefolia又はオオヨモギ(A. montana)などの全草又は葉を乾燥したものであり、収斂性止血及び鎮痛薬としての用途が知られている(非特許文献13)。 Gaiyou is a dried whole plant or leaf such as Artemisia argyi, Artemisia argyi, Artemisia (A. princeps), A. lavandulaefolia or A. montana (Asteraceae) as a convergent hemostatic and analgesic. Applications are known (Non-patent Document 13).
ソボク(蘇木)は、マメ科のスホウ(Caesalpinia sappan)の心材を乾燥したものであり、心臓及び血管収縮作用、嘔吐作用、瀉下作用、催眠作用などが知られており、駆オ血、抗炎症、通経及び鎮痛薬として用いられる(非特許文献14)。 Soboku is a dried product of the heart material of legumes (Caesalpinia sappan), and is known for its heart and vasoconstriction, vomiting, swallowing, and hypnotic effects. It is used as an inflammation, menstruation and analgesic (Non-Patent Document 14).
ホコツシ(補骨脂)はマメ科のオランダビユ(Psoralea corylifolia)の成熟種子を乾燥したものであり、強壮薬としての用途が知られている(非特許文献15)。 Scotch (prosthetic fat) is a product obtained by drying mature seeds of the leguminous Dutch bill (Psoralea corylifolia), and its use as a tonic is known (Non-patent Document 15).
シソヨウ(紫蘇葉)はシソ科のチリメンジソ(Perilla frutescens)の葉を乾燥したものであり、発汗、解熱、鎮咳、鎮痛薬又は魚肉などの中毒に解毒薬として用いることが知られている(非特許文献16)。 Perilla frutescens is a dried leaf of Perilla frutescens and is known to be used as an antidote for intoxication such as sweating, antipyretic, antitussive, analgesic or fish meat (non-patented) Reference 16).
しかし、これらの天然物にはリパーゼ阻害作用及びこれに基づく肥満、高脂血症に対する作用が知られていない。 However, these natural products are not known to have a lipase inhibitory action and an action against obesity and hyperlipidemia based thereon.
本発明の目的は、長期間継続的に服用しても安全かつ効果的な、高脂血症、肥満等のリパーゼ由来の疾患を予防又は改善するための薬剤又は食品を提供することにある。 An object of the present invention is to provide a drug or food for preventing or improving lipase-derived diseases such as hyperlipidemia and obesity that are safe and effective even when continuously taken for a long time.
本発明者らは上記課題を解決するために鋭意検討を行った結果、ある種の生薬又はそのエキスが優れたリパーゼ阻害活性を有すること、及び遺伝的肥満マウスの血清脂質濃度の上昇を抑制することを見出し、本発明を完成した。 As a result of intensive studies to solve the above problems, the present inventors have found that certain herbal medicines or extracts thereof have excellent lipase inhibitory activity and suppress the increase in serum lipid concentration in genetically obese mice. As a result, the present invention has been completed.
すなわち、本発明は、モッカ、フクボンシ、インヨウカク、オンジ、カントンキンセンソウ、ジチョウ、ソウオウ、シンイ、インチンコウ、キョウカツ、カッコウ、ガイヨウ、ソボク、ホコツシ及びシソヨウからなる群から選ばれる1種又は2種以上を配合することを特徴とするリパーゼ阻害剤である。 That is, the present invention includes one or more selected from the group consisting of mokka, fukubonshi, indigo oyster, onji, canton ginseng, biloba, carrot, shinyi, ginseng, kyoukatsu, cuckoo, gaiyou, soboku, shikotsu and perilla. It is a lipase inhibitor characterized by blending.
また、他の本発明は、モッカ、インヨウカク、カントンキンセンソウ、ジチョウ、ソウオウ、シンイ、インチンコウ、キョウカツ、カッコウ、ガイヨウ、ソボク、ホコツシ及びシソヨウからなる群から選ばれる1種又は2種以上を配合することを特徴とする肥満の予防又は改善剤である。 In another aspect of the present invention, one or more selected from the group consisting of mokka, cynomolgus, canton ginseng, biloba, sauou, shinny, ginseng, kyokatsu, cuckoo, mussel, scallop, scallop and perilla are blended. This is an agent for preventing or improving obesity.
本発明に係るモッカ、フクボンシ、インヨウカク、オンジ、カントンキンセンソウ、ジチョウ、ソウオウ、シンイ、インチンコウ、キョウカツ、カッコウ、ガイヨウ、ソボク、ホコツシ及びシソヨウは、そのまま生薬末として、また、水、極性溶媒、それらの混合溶媒などで抽出したエキスとして使用することができるが、水とアルコールを等量混合した溶媒を用いて抽出したエキスが好ましい。 Mokka, Fukubonshi, Yinakukaku, Onji, Canton ginseng, Ginkgo, Sawfish, Shinyi, Ginseng, Kyokatsu, Cuckoo, Guiyou, Sokoku, Shikotsu, and Perilla Although it can be used as an extract extracted with a mixed solvent or the like, an extract extracted with a solvent in which water and alcohol are mixed in equal amounts is preferable.
本発明に係る生薬は、リパーゼ阻害作用に基づく脂質の吸収阻害に有効であることから肥満及び高脂血症の予防又は改善に有効である。 The herbal medicine according to the present invention is effective in preventing or improving obesity and hyperlipidemia because it is effective in inhibiting lipid absorption based on lipase inhibitory action.
本発明により、過食など脂肪類の過剰摂取による血清脂質の上昇、体内脂質の蓄積を予防又は改善でき、肥満、高脂血症等の生活習慣病を予防あるいは改善できる安全性の高い薬剤あるいは食品の提供が可能になった。 According to the present invention, a highly safe drug or food that can prevent or ameliorate an increase in serum lipids due to excessive intake of fats such as overeating, accumulation of body lipids, and prevent or ameliorate lifestyle-related diseases such as obesity and hyperlipidemia Is now available.
本発明で用いる生薬成分は、単品又は混合して用いることができる。
本発明のリパーゼ阻害剤の投与量は、年齢、性別などを考慮して適宜増減できるが、通常成人で1日、原生薬換算量として100mg〜50gの範囲で用いることができ、好ましくは、500mg〜30gである。
The herbal medicine components used in the present invention can be used alone or in combination.
The dosage of the lipase inhibitor of the present invention can be appropriately increased or decreased in consideration of age, gender, etc., but can be used in a range of 100 mg to 50 g as an active ingredient in a normal adult daily, preferably 500 mg. ~ 30 g.
本発明は、発明の効果を損なわない質的及び量的範囲で、ビタミン、キサンチン誘導体、アミノ酸、賦形剤、pH調製剤、清涼化剤、懸濁化剤、消泡剤、粘稠剤、溶解補助剤、崩壊剤、結合剤、滑沢剤、抗酸化剤、コーティング剤、着色剤、矯味矯臭剤、界面活性剤、可塑剤、香料などを配合して、常法により、液剤、錠剤、顆粒剤、散剤、カプセル剤、ドライシロップ剤、チュアブル錠、経粘膜剤などの経口又は非経口製剤とすることができる。 The present invention is a qualitative and quantitative range that does not impair the effects of the invention, vitamins, xanthine derivatives, amino acids, excipients, pH adjusting agents, cooling agents, suspending agents, antifoaming agents, viscous agents, Solubilizing agents, disintegrating agents, binders, lubricants, antioxidants, coating agents, coloring agents, flavoring agents, surfactants, plasticizers, fragrances, etc. are blended, and liquids, tablets, Oral or parenteral preparations such as granules, powders, capsules, dry syrups, chewable tablets and transmucosal agents can be used.
以下に実施例及び試験例を挙げ、本発明をより詳しく説明する。
実施例
モッカを細切後、10倍量の50%エタノールを加え、沸騰後約80℃で30分間ジムロート冷却管を用いて還流抽出し、濾過後エバポレーターを用いてエタノールを留去し、さらに、水分含量が30〜65%程度になるよう濃縮を行うことにより、エキスを得た。
Hereinafter, the present invention will be described in more detail with reference to examples and test examples.
Example After chopping mocca, add 10 times the amount of 50% ethanol, and after boiling, extract with reflux using a Dimroth condenser at about 80 ° C. for 30 minutes, and after filtration, distill off the ethanol using an evaporator. Extracts were obtained by concentrating to a moisture content of about 30-65%.
なお、フクボンシ、インヨウカク、オンジ、カントンキンセンソウ、ジチョウ、ソウオウ、シンイ、インチンコウ、キョウカツ、カッコウ、ガイヨウ、ソボク、ホコツシ及びシソヨウについても同様の抽出法で抽出しエキスを製造した。 In addition, Fukubonshi, Yinokukaku, Onji, Canton ginseng, Ginkgo, Sawfish, Shinyi, Inchinkou, Kyokatsu, Cuckoo, Gaiyo, Sokoku, Shikotsu, and Perilla yam were extracted by the same extraction method to produce an extract.
試験例1(リパーゼ阻害作用の測定)
基質溶液(0.2 mM 4-methylumbelliferyl oleate,シグマ社)50μlに実施例で得た各生薬エキス(2.5% DMSOで溶解)25μL及び酵素溶液(100U/mL pancreatic lipase,TypeVI-S from porcine pancreas,シグマ社)25μlを添加した。37℃で15分間反応させた後、0.1M塩酸(国産化学社)150μL及び0.1Mクエン酸ナトリウム(和光純薬工業社)25μLを加え、励起波長320nm、蛍光波長450 nmにおける蛍光を測定した。なお、各生薬エキスは最終濃度として12.5、25、50及び100μg/mLの各濃度で添加した。
結果を表1及び図1に示した。阻害率は下記式にて算出した。
Test Example 1 (Measurement of lipase inhibitory action)
25 μL of each crude drug extract (dissolved in 2.5% DMSO) and enzyme solution (100 U / mL pancreatic lipase, Type VI-S from porcine pancreas, Sigma) in 50 μl of substrate solution (0.2 mM 4-methylumbelliferyl oleate, Sigma) ) 25 μl was added. After reacting at 37 ° C. for 15 minutes, 150 μL of 0.1 M hydrochloric acid (Kokusan Chemical Co., Ltd.) and 25 μL of 0.1 M sodium citrate (Wako Pure Chemical Industries, Ltd.) were added, and fluorescence at an excitation wavelength of 320 nm and a fluorescence wavelength of 450 nm was measured. Each crude drug extract was added at final concentrations of 12.5, 25, 50, and 100 μg / mL.
The results are shown in Table 1 and FIG. The inhibition rate was calculated by the following formula.
阻害率(%)={1-(Es-Esblank)/(Ec-Ecblank)}×100
Es:サンプルの蛍光強度
Esblank:サンプルブランクの蛍光強度
Ec:対照の蛍光強度
Ecblank:対照ブランクの蛍光強度
Inhibition rate (%) = {1- (Es-Esblank) / (Ec-Ecblank)} × 100
Es: Sample fluorescence intensity
Esblank: Sample blank fluorescence intensity
Ec: Control fluorescence intensity
Ecblank: Fluorescence intensity of the control blank
試験例2(遺伝的肥満マウスの血清脂質上昇抑制作用の測定)
ob/obマウス(6週齢、雄性、日本チャールスリバー社)に実施例で得たソボクエキスを300mg/kg(乾燥エキス換算)の用量で1日1回8週間経口投与した。最終投与後、18〜20時間絶食した。マウスから血液を採取し、遠心分離(3000rpm、20℃、15分)により血清を分離した。血清中のトリグリセライド濃度、遊離脂肪酸濃度及び総コレステロール濃度は、トリグリセライドE−テストワコー、NEFAC−テストワコー及びコレステロールE−テストワコー(いずれも和光純薬工業社)を用いて定量した。
Test Example 2 (Measurement of serum lipid elevation inhibitory activity in genetically obese mice)
The obokob mouse (6 weeks old, male, Nippon Charles River) was orally administered once a day for 8 weeks at a dose of 300 mg / kg (converted to dry extract). Fasted for 18-20 hours after the last dose. Blood was collected from the mice, and serum was separated by centrifugation (3000 rpm, 20 ° C., 15 minutes). The serum triglyceride concentration, free fatty acid concentration, and total cholesterol concentration were quantified using triglyceride E-Test Wako, NEFAC-Test Wako, and cholesterol E-Test Wako (all Wako Pure Chemical Industries, Ltd.).
結果を表2および図3(図3−1〜図3−3)に示した。
表2及び図3から明らかなように、ソボクはob/obマウスの血清脂質上昇を有意に抑制し、高脂血症や肥満を予防または改善することが明らかになった。
The results are shown in Table 2 and FIG. 3 (FIGS. 3-1 to 3-3).
As is clear from Table 2 and FIG. 3, it was revealed that Sokuku significantly suppressed serum lipid elevation in ob / ob mice and prevented or improved hyperlipidemia and obesity.
本発明に係る生薬は、優れたリパーゼ阻害作用を有することから、高脂血症、肥満等のリパーゼ由来の疾患を予防又は改善するための医薬品、食品等に利用可能である。 Since the herbal medicine according to the present invention has an excellent lipase inhibitory action, it can be used in medicines, foods and the like for preventing or ameliorating lipase-derived diseases such as hyperlipidemia and obesity.
Claims (4)
Prophylaxis of obesity characterized by comprising one or more selected from the group consisting of mokka, cypress, canton ginseng, biloba, sauou, shinny, inchinkou, kyokatsu, cuckoo, gaiyou, soboku, scallop and perilla Or an improving agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005111714A JP4929611B2 (en) | 2004-04-09 | 2005-04-08 | Lipase inhibitor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004115539 | 2004-04-09 | ||
JP2004115539 | 2004-04-09 | ||
JP2005111714A JP4929611B2 (en) | 2004-04-09 | 2005-04-08 | Lipase inhibitor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011206870A Division JP5609834B2 (en) | 2004-04-09 | 2011-09-22 | Lipase inhibitor |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005320323A true JP2005320323A (en) | 2005-11-17 |
JP2005320323A5 JP2005320323A5 (en) | 2008-05-22 |
JP4929611B2 JP4929611B2 (en) | 2012-05-09 |
Family
ID=35467844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005111714A Expired - Fee Related JP4929611B2 (en) | 2004-04-09 | 2005-04-08 | Lipase inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4929611B2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007040377A1 (en) * | 2005-10-05 | 2007-04-12 | Angiolab., Inc. | Antiobesity composition |
WO2007066928A1 (en) * | 2005-12-09 | 2007-06-14 | Korea Institute Of Science And Technology | Use of the extract of caesalpinia sappan l. and compounds therefrom |
JP2008512501A (en) * | 2006-02-21 | 2008-04-24 | ドングック ユニバーシティ インダストリー−アカデミック コオペレーション ファンデーション | Composition for prevention and treatment of arteriosclerosis comprising oud extract as a main ingredient |
JP2009046465A (en) * | 2007-07-23 | 2009-03-05 | Maruzen Pharmaceut Co Ltd | Skin cosmetic and food/drink |
JP2010059191A (en) * | 2007-11-21 | 2010-03-18 | Kracie Seiyaku Kk | Aromatase inhibitor |
JP2012502115A (en) * | 2009-11-05 | 2012-01-26 | コリア インスティテュート オブ オリエンタル メディシン | Composition for prevention or treatment of influenza virus-derived diseases |
CN102539597A (en) * | 2011-05-24 | 2012-07-04 | 四川省中医药科学院 | Method for quickly identifying notopterygium incisum seed and notopterygium franchetii seed |
JP2012167060A (en) * | 2011-02-15 | 2012-09-06 | Asahi Group Holdings Ltd | Oral composition |
JP2013032331A (en) * | 2011-07-06 | 2013-02-14 | Kose Corp | Lipid production-inhibiting agent, sebum production-inhibiting agent, and triacylglycerol production-inhibiting agent |
US20140234450A1 (en) * | 2009-03-31 | 2014-08-21 | Industry Foundation Of Chonnam National University | Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products |
KR20150050391A (en) * | 2013-10-28 | 2015-05-11 | 한국 한의학 연구원 | Compositions comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity |
KR20160121912A (en) * | 2015-04-13 | 2016-10-21 | 고려대학교 산학협력단 | Pharmaceutical composition comprising a pharbitidis semen or a mixture of pharbitidis semen extract and corydalis turtschaninovii extract for preventing and treating cardiovascular disease |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58172320A (en) * | 1982-04-02 | 1983-10-11 | Zeria Shinyaku Kogyo Kk | Antihyperlipemia and its preparation |
JPS6140763A (en) * | 1984-08-02 | 1986-02-27 | Osaka Chem Lab | Antiobesity food |
JPH0717873A (en) * | 1993-06-28 | 1995-01-20 | Kirindou:Kk | Enzyme inhibitor |
JPH09176019A (en) * | 1995-12-26 | 1997-07-08 | Suntory Ltd | Carbohydrate-degradative/digestive enzyme inhibitor and medicine and food/beverage formulated therewith |
JPH10287575A (en) * | 1997-04-09 | 1998-10-27 | Ranka Aayurubeedick Haabu Yakuhin Kk | Antiobestic drug |
JP2000102383A (en) * | 1998-09-30 | 2000-04-11 | Nisshin Sugar Mfg Co Ltd | Alfa-glucosidase inhibitor containing extract of perilla frutescens crispa as active ingredient, sugar composition, and food and drink, containing the inhibitor |
JP2002138045A (en) * | 2000-10-30 | 2002-05-14 | Ichimaru Pharcos Co Ltd | Inhibitor for inhibiting differentiation induction of pre- adipocyte |
JP2003113106A (en) * | 2001-10-01 | 2003-04-18 | Pola Chem Ind Inc | Expression promoter of uncoupling protein and composition containing the same |
JP2003146902A (en) * | 2001-11-12 | 2003-05-21 | Nicca Chemical Co Ltd | Lipase activity enhancer, skin care preparation, skin care preparation for slimming and bath medicine for slimming comprising the same lipase activity enhancer |
JP2003321383A (en) * | 2002-04-30 | 2003-11-11 | Bamen Kenichi | Composition for treating climacteric disturbance and composition for increasing sex hormone |
-
2005
- 2005-04-08 JP JP2005111714A patent/JP4929611B2/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58172320A (en) * | 1982-04-02 | 1983-10-11 | Zeria Shinyaku Kogyo Kk | Antihyperlipemia and its preparation |
JPS6140763A (en) * | 1984-08-02 | 1986-02-27 | Osaka Chem Lab | Antiobesity food |
JPH0717873A (en) * | 1993-06-28 | 1995-01-20 | Kirindou:Kk | Enzyme inhibitor |
JPH09176019A (en) * | 1995-12-26 | 1997-07-08 | Suntory Ltd | Carbohydrate-degradative/digestive enzyme inhibitor and medicine and food/beverage formulated therewith |
JPH10287575A (en) * | 1997-04-09 | 1998-10-27 | Ranka Aayurubeedick Haabu Yakuhin Kk | Antiobestic drug |
JP2000102383A (en) * | 1998-09-30 | 2000-04-11 | Nisshin Sugar Mfg Co Ltd | Alfa-glucosidase inhibitor containing extract of perilla frutescens crispa as active ingredient, sugar composition, and food and drink, containing the inhibitor |
JP2002138045A (en) * | 2000-10-30 | 2002-05-14 | Ichimaru Pharcos Co Ltd | Inhibitor for inhibiting differentiation induction of pre- adipocyte |
JP2003113106A (en) * | 2001-10-01 | 2003-04-18 | Pola Chem Ind Inc | Expression promoter of uncoupling protein and composition containing the same |
JP2003146902A (en) * | 2001-11-12 | 2003-05-21 | Nicca Chemical Co Ltd | Lipase activity enhancer, skin care preparation, skin care preparation for slimming and bath medicine for slimming comprising the same lipase activity enhancer |
JP2003321383A (en) * | 2002-04-30 | 2003-11-11 | Bamen Kenichi | Composition for treating climacteric disturbance and composition for increasing sex hormone |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9155773B2 (en) | 2001-12-12 | 2015-10-13 | Angiolab, Inc. | Antiobesity composition |
WO2007040377A1 (en) * | 2005-10-05 | 2007-04-12 | Angiolab., Inc. | Antiobesity composition |
WO2007066928A1 (en) * | 2005-12-09 | 2007-06-14 | Korea Institute Of Science And Technology | Use of the extract of caesalpinia sappan l. and compounds therefrom |
JP2008512501A (en) * | 2006-02-21 | 2008-04-24 | ドングック ユニバーシティ インダストリー−アカデミック コオペレーション ファンデーション | Composition for prevention and treatment of arteriosclerosis comprising oud extract as a main ingredient |
JP2009046465A (en) * | 2007-07-23 | 2009-03-05 | Maruzen Pharmaceut Co Ltd | Skin cosmetic and food/drink |
JP2010059191A (en) * | 2007-11-21 | 2010-03-18 | Kracie Seiyaku Kk | Aromatase inhibitor |
JP4521476B2 (en) * | 2007-11-21 | 2010-08-11 | クラシエ製薬株式会社 | Aromatase inhibitor |
US9649351B2 (en) * | 2009-03-31 | 2017-05-16 | Industry Foundation Of Chonnam National University | Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products |
US20140234450A1 (en) * | 2009-03-31 | 2014-08-21 | Industry Foundation Of Chonnam National University | Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products |
US8591962B2 (en) | 2009-11-05 | 2013-11-26 | Korea Institute Of Oriental Medicine | Composition for preventing and treating influenza-virus-induced diseases |
JP2012502115A (en) * | 2009-11-05 | 2012-01-26 | コリア インスティテュート オブ オリエンタル メディシン | Composition for prevention or treatment of influenza virus-derived diseases |
JP2012167060A (en) * | 2011-02-15 | 2012-09-06 | Asahi Group Holdings Ltd | Oral composition |
CN102539597B (en) * | 2011-05-24 | 2014-03-26 | 四川省中医药科学院 | Method for quickly identifying notopterygium incisum seed and notopterygium franchetii seed |
CN102539597A (en) * | 2011-05-24 | 2012-07-04 | 四川省中医药科学院 | Method for quickly identifying notopterygium incisum seed and notopterygium franchetii seed |
JP2013032331A (en) * | 2011-07-06 | 2013-02-14 | Kose Corp | Lipid production-inhibiting agent, sebum production-inhibiting agent, and triacylglycerol production-inhibiting agent |
KR20150050391A (en) * | 2013-10-28 | 2015-05-11 | 한국 한의학 연구원 | Compositions comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity |
KR101672274B1 (en) * | 2013-10-28 | 2016-11-04 | 한국 한의학 연구원 | Compositions comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity |
KR20160121912A (en) * | 2015-04-13 | 2016-10-21 | 고려대학교 산학협력단 | Pharmaceutical composition comprising a pharbitidis semen or a mixture of pharbitidis semen extract and corydalis turtschaninovii extract for preventing and treating cardiovascular disease |
WO2016167493A3 (en) * | 2015-04-13 | 2016-12-08 | 고려대학교 산학협력단 | Pharmaceutical composition for preventing or treating cardiovascular diseases, containing pharbitis seed extract or mixture of pharbitis seed extract and corydalis extract as active ingredient |
KR101713557B1 (en) | 2015-04-13 | 2017-03-22 | 고려대학교 산학협력단 | Pharmaceutical composition comprising a pharbitidis semen or a mixture of pharbitidis semen extract and corydalis turtschaninovii extract for preventing and treating cardiovascular disease |
Also Published As
Publication number | Publication date |
---|---|
JP4929611B2 (en) | 2012-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4929611B2 (en) | Lipase inhibitor | |
KR102056108B1 (en) | Composition for removing hangover and improving liver function | |
JP3966689B2 (en) | Lipase inhibitor | |
AU2002364213B2 (en) | Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors | |
KR100372561B1 (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
JP2016529221A (en) | Medicinal composition derived from amaranth extract with concentrated nitrate content and method for preparing the same | |
JP2004075638A (en) | Functional material having action to suppress increase of blood sugar level and suppress increase of blood pressure | |
JP5609834B2 (en) | Lipase inhibitor | |
JP2013501778A (en) | HEALTH SUPPLEMENTAL, FEED, PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING THE SAME CONTAINING CHIASEED AND MACA | |
JP2002275077A (en) | Lipase inhibitor | |
CN115607583B (en) | Composition containing silybum marianum extract and application of composition in preparation of dietary supplements | |
EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
KR101046787B1 (en) | Hangover drink composition | |
JP4982946B2 (en) | Lipase inhibitor | |
JP5310781B2 (en) | Lipase inhibitor | |
KR101728629B1 (en) | A Method for Manufacturing Aged Black Garlic Tablets Composition | |
JP2009203209A (en) | Composition for blood sugar reduction and/or anti-obesity containing material originated from bark of acacia | |
JP4907280B2 (en) | Lipase inhibitor | |
KR100416650B1 (en) | Extract Polygonatum and composition caontaining the same with hypocholesterolemic and hypoglycemic activities | |
KR101248378B1 (en) | Pharmaceutical composition for arthritis treatment and prevention | |
JP4706174B2 (en) | α-Glucosidase inhibitor | |
KR20160008135A (en) | Composition for preventing or alleviating hangover comprising extracts of catalpa ovata g. don | |
JP5706142B2 (en) | Blood glucose lowering agent, visceral fat accumulation inhibitor, TG lowering agent, faecal fat excretion promoter containing ethanol extract of Fuyubodaiju flower as an active ingredient | |
KR100773246B1 (en) | Composition comprising of trillium kamtschaticum extracts as an effective ingredient for decreasing weight gain and lowering plasma glucose level | |
Andalib et al. | Comparison of Hepatoprotective Activity of Cichorium Intybus and Cynara Scolymus Extracts Against Paracetamol Induced Hepatotoxicity in Broiler Chicken |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080407 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080407 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110922 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120117 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120130 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150224 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150224 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |